Cargando…
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
OBJECTIVE: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about its toxicity, inconvenience and acceptability to patients. The purposes of this study were to de...
Autores principales: | Blinman, Prunella, Gainford, Corona, Donoghoe, Mark, Martyn, Julie, Blomfield, Penny, Grant, Peter, Kichenadasse, Ganessan, Vaughan, Michelle, Brand, Alison, Shannon, Catherine, Gebski, Val, Stockler, Martin, Friedlander, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805917/ https://www.ncbi.nlm.nih.gov/pubmed/24167672 http://dx.doi.org/10.3802/jgo.2013.24.4.359 |
Ejemplares similares
-
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016) -
Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
por: Obermair, Andreas, et al.
Publicado: (2021) -
Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
por: Farrell, Rhonda, et al.
Publicado: (2021) -
Impact of the censoring distribution on time-to-event problems in the presence of competing risks
por: Donoghoe, Mark W, et al.
Publicado: (2011) -
The importance of censoring in competing risks analysis of the subdistribution hazard
por: Donoghoe, Mark W., et al.
Publicado: (2017)